Therapie des metastasierten Urothelkarzinoms

Translated title of the contribution: Therapy of metastatic urothelial cancer

H. E. Fender, F. F. Dreßler, M. C. Hupe, M. W. Kramer, A. S. Merseburger*

*Corresponding author for this work


The gold standard for the therapy of metastatic or inoperable urothelial cancer is the combination of gemcitabine and cisplatin as first-line treatment and immunotherapy with pembrolizumab, atezolizmab or nivolumab as second-line treatment. For patients who are not eligible for standard cisplatin-containing chemotherapy, pembrolizumab and atezolizumab are first-line treatment options. In the future, targeted therapies and immunotherapeutics, e.g., in maintenance therapy, will influence the therapeutic landscape of advanced urothelial carcinoma.

Translated title of the contributionTherapy of metastatic urothelial cancer
Original languageGerman
JournalBest Practice Onkologie
Issue number9
Pages (from-to)368-376
Number of pages9
Publication statusPublished - 01.09.2020

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Therapy of metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this